Engflag

Prazocid

Quick links to important sections

Prazocid

Prazocid_PL

Method of action: Antiulcer, Drugs For Acid Related Disorders, Proton Pump Inhibitor

Treatment option: Gastroesophageal Reflux Disease, Hypersecretory Conditions, Heartburn, Pathological Hypersecretory Conditions, Reflux, Zollinger-Ellison Syndrome, Esophagitis, Erosive Esophagitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prazocid

Property Description
Active Ingredient Pantoprazole (as Pantoprazole sodium sesquihydrate)
Form Delayed-Release Tablet
Pharmacological Class Proton Pump Inhibitor (PPI)
Common Use Acid Reduction
Origin Synthetic (Single-ingredient)

What Type of Medicine is Prazocid?

Prazocid is a prescription medication whose active ingredient is Pantoprazole, and it belongs to a powerful class of drugs known as Proton Pump Inhibitors (PPIs).

As a PPI, Prazocid is fundamentally an acid-reducer designed to effectively decrease the amount of corrosive acid the stomach produces. The active substance, Pantoprazole, is clinically recognized for its high potency. The medication is an entirely synthetic, single-ingredient compound, meaning its structure is created chemically and it works solely through the action of the Pantoprazole component.

Form and Composition: The Delayed-Release Tablet

Prazocid is administered orally as a specialized Delayed-Release Tablet, which is designed to protect the medicine from the stomach's acid.

The tablet contains the active drug, typically Pantoprazole sodium sesquihydrate, along with inactive ingredients and a specialized enteric coating. This formulation is a key differentiating feature, as this delayed-release mechanism ensures the maximum amount of the active ingredient reaches the site of absorption effectively. This design is necessary for the drug's effectiveness, as the formulation is designed to provide gastro-resistance. This means the tablet is specifically engineered to deliver the medication to the correct part of the digestive tract, ensuring the patient receives the full therapeutic benefit.

General Purpose: Reducing Stomach Acid Production

The general purpose of Prazocid is to provide a long-lasting, profound reduction in the amount of acid produced by the stomach.

It achieves this by working directly on the cells in the stomach lining that create the acid, effectively "shutting down" the proton pumps. This targeted action is intended to provide sustained relief. The resulting environment of low acidity is essential for relieving acid-related symptoms, allowing irritation and inflammation to heal, which is the overall therapeutic goal of the medication.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Prazocid?

Prazocid: Official Safety Profile and Adverse Reactions

The safety profile for Prazocid (Pantoprazole) is formally documented by regulatory authorities, classifying possible adverse reactions by frequency and the body system affected. These classifications ensure that common and rare safety concerns are clearly communicated to align with official labeling.

Frequency-Classified Adverse Reactions

The most frequently reported events in regulatory documents are classified as common. These typically include gastrointestinal effects such as diarrhea, abdominal pain, flatulence, nausea, and vomiting, alongside headache and dizziness. Reactions classified as uncommon include temporary increases in liver enzymes and certain skin reactions like rash or pruritus.

Serious and Duration-Related Safety Considerations

Official labeling defines several serious but rare adverse reactions, including severe skin conditions such as Stevens-Johnson Syndrome (SCARs), Anaphylaxis, and specific types of kidney inflammation known as Acute Tubulointerstitial Nephritis (TIN). Use of this medication may also be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD).

Certain safety concerns are specifically linked to the duration of exposure. Long-term use (typically one year or longer) is officially associated with an increased risk for osteoporosis-related bone fracture of the hip, wrist, or spine, and the development of hypomagnesemia (low blood magnesium levels). The risk of developing Fundic Gland Polyps also increases with chronic exposure.

Constraints and Special Populations

Safety notes are present for specific patient groups, including those with severe hepatic impairment, who may require particular observation due to the potential for increased systemic exposure. Co-administration is restricted with certain HIV protease inhibitors, such as atazanavir, where reduced efficacy of the antiviral could occur. All safety statements align strictly with official government prescribing information.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Prazocid (Pantoprazole) overdose is based on reports of limited clinical experience with high doses. This information strictly details the official manifestations and the regulatory-mandated emergency actions required.

Documented Overdose Profile

Domain Official Regulatory Statement
Documented Manifestations Symptoms observed in reported cases are typically non-specific, often representing an exaggeration of known adverse effects, which may include headache, dry mouth, nausea, vomiting, abdominal pain, and diarrhea.
Antidote Information No specific antidote is known or available for Pantoprazole overdose.
Management Principle Treatment is described as symptomatic and supportive. Due to high plasma protein binding, the medicine is not effectively removed by hemodialysis in overdose situations.
Population Notes Official documents do not define separate overdose considerations for specific populations (e.g., pediatric, geriatric, or renally impaired) regarding acute management.

Immediate Actions and When to Seek Urgent Help

All suspected overdoses require immediate professional medical attention.

  • Seek immediate medical attention or contact a Poison Control Center following any suspected overdose of Prazocid.
  • Emergency services must be contacted immediately if an individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened, as stated in health authority guidance.

This structure describes how governmental regulatory documents define the overdose profile, emphasizing the immediate need for medical evaluation and the focus on supportive care due to the absence of a known antidote.

Therapeutic Uses of Prazocid

What Prazocid Treats: Main Uses and Benefits

Prazocid is commonly used for conditions involving inflammatory or irritative processes related to excess stomach acid. It helps manage symptom clusters that may become intense or disruptive. This supportive approach contributes to easing the overall symptom load and supports general well-being during symptomatic phases. In clinical use, the medication addresses damage from acid reflux and conditions where the stomach produces too much acid.

The primary therapeutic focus of Prazocid is considered relevant in the domains of Erosive Esophagitis, Gastroesophageal Reflux Disease (GERD), and the management of Pathological Hypersecretory Conditions like Zollinger-Ellison Syndrome. It is also relevant for easing the symptomatic distress associated with peptic ulcers and may assist with reducing the likelihood of their recurrence.

It helps address symptoms that interfere with daily functioning, particularly frequent heartburn and the regurgitation of stomach contents. It is applied in clinical settings that involve acute or unstable symptom patterns, such as during initial supportive courses or long-term management protocols.

Quick Fact: Managing Symptoms of Chronic Acid Reflux
Prazocid contributes to improved comfort during periods of heightened symptoms by managing heightened physiological activity, helping patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Prazocid?

The population eligibility for Prazocid (Pantoprazole) is strictly defined by government regulatory guidelines, detailing which groups are permitted, restricted, or absolutely prohibited from use.

Contraindications and Restrictions

Eligibility Status Description (Official Regulatory Wording)
Absolutely Prohibited Patients with a known hypersensitivity to Pantoprazole, any substituted benzimidazoles, or any component of the formulation. It is also contraindicated for patients taking rilpivirine-containing products.
Restricted Use Patients with severe hepatic impairment have limited eligibility, often requiring a restricted daily dose as advised by regulatory labeling. Use during pregnancy is conditional, allowed only if the potential benefit outweighs the risk.

Age-Based Eligibility

Adults (18 years and older) are approved for all labeled indications. Pediatric use is not established and not recommended for children younger than 5 years of age. However, the medicine is approved for certain indications in children aged 5 years and older. No specific safety or efficacy differences are noted for the geriatric population.

Other Limitations

Use is not recommended for women who are breastfeeding, as the drug is excreted in human milk. For patients with renal impairment, dose adjustment is generally not required, meaning eligibility remains unrestricted by this condition.

What should I know about interactions with other medicines?

Prazocid Interactions with other medicines and products

Official regulatory information describes Prazocid's interaction profile based on its effect on stomach acidity, documented metabolic patterns, and post-marketing surveillance reports.

Category Officially Documented Constraint or Requirement
Contraindicated Combinations Co-administration is contraindicated with Rilpivirine-containing products [2.1]. The use of Atazanavir and Nelfinavir is not recommended due to significant reductions in their plasma concentrations [1.4, 2.3].
Exposure-Modifying Substances Prazocid can reduce the absorption of medicines dependent on gastric pH for bioavailability, including Ketoconazole, Itraconazole, Erlotinib, and Iron Salts [1.4]. Co-administration with high-dose Methotrexate may elevate and prolong serum levels of the antineoplastic drug [3.4].
Pharmacodynamic Monitoring Coumarin Anticoagulants (e.g., Warfarin) require monitoring because post-marketing reports indicate a potential for increased International Normalized Ratio (INR) and prothrombin time [3.6]. The antiplatelet effect of Clopidogrel is officially stated to have no clinically important effect when co-administered [1.5].
Test Interference / Timing Prazocid may produce false-positive results in some urine screening tests for Tetrahydrocannabinol (THC) metabolites [1.4]. To avoid interference with tumor investigations, treatment must be temporarily stopped for at least 14 days before measuring Chromogranin A ( CgA) levels [3.4].

The overall interaction structure is primarily defined by the requirement to manage the reduced absorption of acid-sensitive medications and the necessary monitoring protocols for specific co-administered drugs. Regulatory labeling addresses the interaction with CYP2C19 substrates by confirming that no clinically significant effect was observed for many common medicines. Long-term use establishes the context for potential Vitamin B12 deficiency due to the sustained reduction in gastric acid [1.4, 2.4].

Mechanism of Action

Prazocid's mechanism centers on the irreversible inhibition of the H^+/ K^+-ATPase enzyme system, which is the final machinery responsible for acid secretion in the stomach. The active form of the drug forms a strong, covalent bond with specific residues on the pump, permanently deactivating it. This molecular blockade results in a major and long-lasting suppression of acid secretion by causing the cessation of hydrogen ion ( H^+) efflux.

The drug is an inactive prodrug that must first be chemically converted by the highly acidic environment inside the parietal cells before it can bind, confining its action to the acid-secreting cells. The resulting physiological effect is long-lasting because acid secretion can only resume once the stomach cells can synthesize new, functional enzymes to replace the inhibited ones. This mechanism results in a long-duration elevation of intragastric pH which is determined by cellular enzyme synthesis rather than plasma concentration.

Dosage and Administration Information

How Prazocid is Used: Official Administration Guidelines

Prazocid, with the active ingredient Pantoprazole, is administered based on standardized protocols to ensure proper use. The medicine is available for administration via two approved routes: the Oral (PO) route, primarily as a delayed-release tablet or suspension, and the Intravenous (IV) Infusion route, which is utilized when oral administration is not feasible.

Standardized Dosing and Frequency

The typical regimen for the initial treatment of conditions like erosive esophagitis is 40 mg once daily. For long-term management or conditions requiring greater acid suppression, such as pathological hypersecretory states, the dose is often adjusted, starting at 40 mg twice daily and potentially increasing to higher doses administered in divided use.

Administration Detail Official Instruction Summary
Oral Tablet Intake Must be swallowed whole; the tablet should not be split, crushed, or chewed to preserve the essential delayed-release enteric coating. Tablets may be taken with or without food.
IV Use Duration The intravenous route is a temporary measure, typically limited to a period of 7 to 10 days, with a recommended switch to the oral form as soon as possible.
Treatment Course Initial treatment courses for conditions like erosive esophagitis are often prescribed for a limited duration, usually up to 8 weeks, while maintenance therapy is long-term.

Population and Procedural Constraints

Established guidelines include specific dose restrictions for certain populations. For instance, in some regions, the daily dose generally must not exceed 20 mg in patients with severe hepatic impairment. Regarding missed doses, if one is forgotten, it should be taken as soon as possible unless it is almost time for the next scheduled dose, in which case the missed dose must be skipped; doses should not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prazocid

Evidence for Short-Term Treatment of Erosive Esophagitis

Prazocid has been the subject of clinical evaluation in the form of large, Randomized Controlled Trials (RCTs) and systematic meta-analyses. These studies monitored outcomes related to the physical healing of the esophageal lining and patient-reported outcomes describing perceived discomfort, particularly the frequency of heartburn and acid regurgitation. Studies monitored how symptoms evolved in adult populations and in pediatric patients aged five years and older.

It is important to note that research findings for the medicine have not been established for children younger than five years of age. Furthermore, the core evidence for this initial healing phase is derived from research exploring short-term changes, typically up to the standard eight-week treatment window.

Evidence for Use in Specific Acute Clinical Settings

Research has also been conducted using large, multi-center, blinded Randomized Controlled Trials (RCTs) to explore its use in specific clinical situations, such as in critically ill adults. These studies monitored outcomes related to the rate of occurrence of clinically important upper gastrointestinal bleeding episodes in critically ill adults requiring mechanical ventilation. The findings are specific to these acute, high-risk populations.

Evidence for Long-Term Maintenance of Healing

Following initial healing, controlled long-term clinical trials have examined whether continued treatment was associated with a lower rate of symptoms and damage returning. These studies monitored outcomes, looking specifically at the rate at which the healed lining remained free of new erosions or showed relapse. The certainty remains low regarding the very long-term outcomes of this maintenance approach, as controlled studies typically do not report findings extending beyond a one-year observation period.

Evidence for Managing Pathological Acid Hypersecretion

Research exploring pathological hypersecretory conditions, such as the rare Zollinger-Ellison Syndrome, primarily involved long-term open-label clinical studies and individual case series. Studies monitored outcomes linked to severe acid-related symptoms, such as pain, and tracked changes in gastric acid secretion levels. The evidence for this rare disease management is limited, as the research relies on studies where sample sizes were modest, meaning certainty remains low regarding findings from these specialized subgroups.

Frequently Asked Questions (FAQ)

Common questions about Prazocid (FAQ)

Q: What is Prazocid used for?

Prazocid is authorized for the management of hypertension (high blood pressure) and to aid in improving symptoms associated with benign prostatic hyperplasia (BPH).

Q: How does Prazocid work in the body?

Prazocid functions as an alpha-1 blocker. It influences the alpha-1 adrenergic receptors, which may contribute to the relaxation of certain muscles, potentially leading to effects such as blood vessel dilation and improved urine flow.

Q: What are common observations regarding Prazocid use?

The most frequently reported observations in clinical study settings included dizziness, headache, fatigue, and nausea. It is important to note that not everyone experiences these occurrences.

Q: Is Prazocid safe for everyone?

Prazocid is not suitable for everyone. Individuals with a known hypersensitivity to the medication, or certain other specific health conditions, may be advised against its use. A healthcare provider is the appropriate source for assessing individual suitability.

Q: What if I miss a dose of Prazocid?

If a scheduled administration is missed, patients are generally advised to consult their prescribing healthcare professional or follow the specific guidance provided on the patient information leaflet that accompanied the product.

How should Prazocid be stored and disposed of?

How to Store and Dispose of Prazocid

Prazocid (Pantoprazole Delayed-Release Tablets) must be stored and handled according to specific government-approved regulatory requirements to maintain product stability and ensure safety.

Official Storage Conditions

Requirement Specific Condition
Temperature Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F), permitting short excursions between 15 C and 30 C.
Protection Must be protected from moisture and excessive heat.
Container Rule Keep the medication in its original container and ensure the container is tightly closed when not in use.
Child Safety Must be kept strictly out of the reach and sight of children.

Disposal Instructions

Unused or expired Prazocid should be disposed of via a drug take-back program. If one is unavailable, the medication must be mixed with an undesirable substance (such as dirt) and sealed in a container before being discarded in the household trash. It is explicitly stated that Prazocid must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Prazocid found in:

A-Z Index: